(VIP-neurotensin) hybrid antagonist
10
relevant articles (0 outcomes,
0 trials/studies)
found for this Bio-Agent
Description:
contains fractions of VIP peptide & neurotensin; 28 amino acid sequence given in first source; consists of an N-terminal sequence from neurotensin and the 22 C-terminal amino acids of vasoactive intestinal peptide (VIP); inhibits VIP receptor
Also Known As:
(Lys(1)-Pro(2,5)-Arg(3,4)-Tyr(6))VIP(7-28); Lys-Pro-Arg-Arg-Pro-Tyr-VIP(7-28); VIP Hybrid; VIP-NE hybrid antag; VIPhyb; lysyl-prolyl-arginyl-arginyl-prolyl-tyrosyl-VIP(7-28); neurotensin(6-11)VIP(7-28)
Bio-Agent Context: Research Results